AN INFUSION OF RELIEF FROM CKD-ASSOCIATED PRURITUS1
Tap below to access the latest data on KAPRUVIA®
Identifying and assessing CKD-associated Pruritus
A proposed algorithm for the evaluation of this debilitating condition
Improving itch-related sleep disruption with KAPRUVIA®
A post-hoc analysis of Phase III studies
The chronicity of CKD-associated Pruritus and its impact on clinical outcomes
Understanding the potential value of repeated assessment
Get the latest updates from CSL Vifor
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should also be reported to CSL Vifor at safety@viforpharma.com.
KAPRUVIA® is indicated for use in adult, in-center haemodialysis patients suffering from moderate-to-severe CKD-associated Pruritus.1
Printed SmPC available upon request at the booth, abbreviated SmPC available at the content corner at the booth.
KAPRUVIA® (difelikefalin) is approved in the European Union, Iceland, Norway, Switzerland and the United Kingdom. Best efforts have been undertaken to ensure compliance with EFPIA Code and the EU SmPC. The SmPC can vary from country to country; before prescribing, always refer to the applicable local SmPC.
References & footnotes
References
1. KAPRUVIA® Summary of Product Characteristics, Date of authorization: 25.04.2022; Last updated: 14.10.2024.
Additional
HQ-DFK-2500068 | April 2025